| Literature DB >> 26156837 |
Farid Talih1, Elias Ghossoub1.
Abstract
It is well documented in the literature that noradrenergic pathways are key in the manifestation of opioid withdrawal symptoms, which is why clonidine is used as an off-label agent in opioid detoxification regimens given its anti-sympathetic properties. Moxonidine is a selective I1-imidazoline receptor agonist, similar to clonidine but with no α2-adrenergic agonist activity and subsequently fewer side effects. We report the case of a 33-year-old woman with a 15-year history of tramadol use who was admitted voluntarily for detoxification. She was started on moxonidine and had an uneventful detoxification. Two months after discharge, the patient maintained tramadol abstinence with good tolerability to moxonidine. To the best of our knowledge, this has not been previously reported in the medical literature. 2015 BMJ Publishing Group Ltd.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26156837 PMCID: PMC4499750 DOI: 10.1136/bcr-2015-210444
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X